From Recent Issues

Addressing Unmet Need in the Management of Patients With ER+/HER2–, ESR1-Mutated Metastatic Breast Cancer: Clinician’s Perspective

Abstract: Approximately 70% of breast tumors are ER+ and HER2–. First-line treatment that combines endocrine therapy (AIs, SERMs, and SERDs) with a CDK4/6 inhibitor is the […]

Overcoming the Hurdles: Surmounting Acquired Resistance to Anti-EGFR Therapy in Metastatic Colorectal Cancer

Abstract: Colorectal cancer is the third most prevalent cancer type in the United States, with an alarming incidence and mortality rate, especially among individuals younger than […]

Surgical Resection Criteria and Neoadjuvant Therapies for Intrahepatic Cholangiocarcinoma

Abstract: The staging of intrahepatic cholangiocarcinoma (ICC) is complex, and there is no consensus among international cancer groups on how to most appropriately select candidates with […]

Supplements

Highlights in Metastatic Breast Cancer from the 2022 San Antonio Breast Cancer Symposium

A Review of Selected Presentations from SABCS 2022 • San Antonio, TX  •  December 6-10, 2022 EMERALD Phase 3 Trial of Elacestrant Versus Standard of Care […]

Progress in the Treatment of Breast Cancer: Increased Survival, Improved Patient Experience, and Advances in Drug Formulation

A Review of Selected Presentations From the 2022 San Antonio Breast Cancer Symposium® • December 6-11, 2022  •  San Antonio, Texas  Sacituzumab Govitecan vs Treatment of […]

Year-End Highlights in Metastatic Triple-Negative Breast Cancer from the 2022 American Society of Clinical Oncology Annual Meeting, and the European Society for Medical Oncology Congress and Breast Cancer Congress

A Review of Selected Presentations from ASCO 2022, Chicago, IL, June 3-7, 2022; ESMO Breast Cancer Congress 2022, Berlin, Germany, May 3-5 2022; and ESMO Congress […]